EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Advances in the treatment of Hodgkin's lymphoma (Review)

Yuxuan Che, Xiaolei Ding, Liye Xu, Jian Zhao, Xian Zhang, Na Li, Xiuhua Sun

International Journal of Oncology · 04.04.2023 · 62 (5)

DOI: 10.3892/ijo.2023.5509 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Oncology, online erschienen am 04.04.2023. Verfasst von Yuxuan Che und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116021, P.R. China. Hauptthemen laut MEDLINE: Hodgkin Disease, Immunoconjugates. Die Arbeit wurde bisher 11-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hodgkin's lymphoma (HL) is a unique B‑cell lymphoproliferative malignancy that has a critical pathogenesis characterized by a sparse population of Hodgkin and Reed‑Sternberg cells surrounded by numerous dysfunctional immune cells. Although systemic chemotherapy with or without radiotherapy, has significantly improved the prognosis of the majority of patients with HL, a subset of patients remains refractory to first‑line therapy or relapse after achieving an initial response. With the increased understanding of the biology and microenvironment of HL, novel strategies with notable efficacy and manageable toxicity, including targeted therapies, immunotherapy and cell therapy have emerged. The present review summarizes the progress made in developing novel therapies for HL and discusses future research directions in HL therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hodgkin DiseaseImmunoconjugatesHumansBrentuximab VedotinTreatment OutcomeNeoplasm Recurrence, LocalTumor Microenvironment

Stichwörter der Autor:innen

Hodgkin's lymphomabrentuximab vedotincell therapyimmunotherapynovel therapiestargeted therapy

Substanzen

Brentuximab VedotinImmunoconjugates

Autor:innen und Institutionen

  • Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116021, P.R. China.

Zitieren

APA

Che, Y., Ding, X., Xu, L., Zhao, J., Zhang, X., Li, N., & Sun, X. (2023). Advances in the treatment of Hodgkin's lymphoma (Review). International Journal of Oncology, 62(5). https://doi.org/10.3892/ijo.2023.5509

Vancouver

Che Y, Ding X, Xu L, Zhao J, Zhang X, Li N, et al. Advances in the treatment of Hodgkin's lymphoma (Review). International Journal of Oncology. 2023;62(5). doi:10.3892/ijo.2023.5509

BibTeX
@article{Che2023,
  author = {Che, Yuxuan and Ding, Xiaolei and Xu, Liye and Zhao, Jian and Zhang, Xian and Li, Na and Sun, Xiuhua},
  title = {Advances in the treatment of Hodgkin's lymphoma (Review)},
  journal = {International Journal of Oncology},
  year = {2023},
  volume = {62},
  number = {5},
  doi = {10.3892/ijo.2023.5509}
}
Kostenlos starten →